Mark Breidenbach
Stock Analyst at Oppenheimer
(1.70)
# 3,261
Out of 4,918 analysts
56
Total ratings
32.2%
Success rate
0.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $11.04 | +171.74% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.08 | +1,103.70% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.89 | +799.47% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $7.42 | +1,180.32% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $3.37 | +641.84% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.74 | +1,256.48% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $13.70 | +1,651.82% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.82 | +4,088.48% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.48 | +372.97% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.95 | +1,541.03% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $2.68 | +459.70% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.48 | +8,008.11% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.47 | +663,165.31% | 2 | May 12, 2020 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $11.04
Upside: +171.74%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.08
Upside: +1,103.70%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.89
Upside: +799.47%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $7.42
Upside: +1,180.32%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $3.37
Upside: +641.84%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.74
Upside: +1,256.48%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $13.70
Upside: +1,651.82%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.82
Upside: +4,088.48%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.48
Upside: +372.97%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.95
Upside: +1,541.03%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.68
Upside: +459.70%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.48
Upside: +8,008.11%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.47
Upside: +663,165.31%